AIM
LFCR icon

Arcadia Investment Management’s Lifecore Biomedical LFCR Stock Holding History

Arcadia Investment Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2,650
Closed -$32K – 394
2017
Q1 		$32K Buy
+2,650
New +$33.5K 0.01% 269
2016
Q3 		– Sell
-2,795
Closed -$30K – 392
2016
Q2 		$30K Buy
+2,795
New +$30.8K 0.01% 267

Other funds holding LFCR

NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return

Arcadia Investment Management's LFCR Position: Q2 2017 in Review

Arcadia Investment Management sold out of Lifecore Biomedical (LFCR) in Q2 2017, closing a stake of 2,650 shares — an estimated $32K sold.

Arcadia Investment Management first reported a position in LFCR in Q2 2016 and held it in 2 quarters. The position peaked at $32K in Q1 2017. 94 funds tracked by Wall St. Rank hold LFCR as of Q2 2017.

  • Arcadia Investment Management reported no remaining Lifecore Biomedical position as of Q2 2017 after selling out during the quarter.
  • Arcadia Investment Management sold 2,650 Lifecore Biomedical shares in Q2 2017, an estimated $32K.
  • Arcadia Investment Management first reported a position in Lifecore Biomedical in Q2 2016 and held it in 2 quarters.
  • Arcadia Investment Management's Lifecore Biomedical position peaked at $32K in Q1 2017.
  • 94 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2017.

Based on Arcadia Investment Management's 13F filing for Q2 2017, filed 3 Aug 2017.